Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment

Journal of Immunotherapy

Volumn 37, Issue 2, 2014, Pages 115-122

  Liu, Jun ^a,b,c   Li, Hui ^a,b   Cao, Shui ^a,b   Zhang, Xinwei ^a,b   Yu, Jinpu ^a,b   Qi, Jing ^a,b   An, Xiumei ^a,b   Yu, Wenwen ^a,b   Ren, Xiubao ^a,b   Hao, Xishan ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

adoptive immunotherapy; advanced epithelial ovarian cancer; cytokine induced killer cells; maintenance therapy; prognosis

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; CARBOPLATIN; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894478965     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000021     Document Type: Article

References (48)

1. Fleming GF, Ronnett BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009:763-836.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology. 2011;25: 928-934.
4. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol. 1992;166:504-511.
5. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol. 1995;16:349-356.
6. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
7. Bookman MA, Brady MF, Mcguire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
8. Pfisterer J,Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036-1045.
9. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol. 2006;24:1127-1135.
10. Binaschi M, Simonelli C, Goso C, et al. Maintenance therapy in ovarian cancer: molecular basis and therapeutic approach. Exp Ther Med. 2011;2:173-180.
11. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
12. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365: 2484-2496.
13. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114: 195-198.
14. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Cytotoxic Tlymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother. 2012;35:196-204.
15. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol. 1994;16:198-210.
16. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
17. Kim HM, Kang JS, Lim J, et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res. 2007;30:1464-1470.
18. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305-310.
19. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
20. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, et al. Largescale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother. 2002;51:440-448.
21. Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol. 1996;169:85-90.
22. Zhao Q, Zhang H, Li Y, et al. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res. 2010;29:118.
23. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673-684.
24. Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy. 2012;14:483-493.
25. Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokineinduced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006;12:1859-1867.
26. Ren X, Yu J, Liu H, et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm. 2006;21:22-33.
27. Rustin GJ, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 2001;19:4054-4057.
28. Alexandre J, Brown C, Coeffic D, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer. 2012; 106:633-637.
29. Li R, Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012;61:2125-2133.
30. Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18:1751-1759.
31. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokineinduced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009;11:1076-1083.
32. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21: 750-755.
33. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21:1673-1679.
34. Dou J, Wang Y, Wang J, et al. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiol. 2009;214:483-492.
35. Papi A, Stanciu LA, Papadopoulos NG, et al. Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells. J Infect Dis. 2000;181:1780-1784.
36. Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103:3065-3072.
37. Lu X, Zhu A, Cai X, et al. Role of NKG2D in cytokineinduced killer cells against multiple myeloma cells. Cancer Biol Ther. 2012;13:623-629.
38. Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
39. Yu J, Ren X, Cao S, et al. Th1 polarization and apoptosisinducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm. 2006;21:276-284.
40. Yu J, Zhang W, Jiang H, et al. CD4+T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radiopharm. 2008;23:342-354.
41. Becker Y. Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Res. 2006;26:1113-1134.
42. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48: 353-362.
43. Rayman P, Uzzo RG, Kolenko V, et al. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Cancer J Sci Am. 2000;6(suppl 1):S81-S87.
44. Ladhams A, Schmidt C, Sing G, et al. Treatment of nonresectable hepatocellular carcinoma with autologous tumorpulsed dendritic cells. J Gastroenterol Hepatol. 2002;17: 889-896.
45. Cho MY, Joh YG, Kim NR, et al. T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg. 2002;91:172-177.
46. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DCactivated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013;62:65-73.
47. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101-116.
48. Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013; 31:413-441.